[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2005060694A3 - Treatment of neurologic disorders with inhibitors of 11beta-hsd1 - Google Patents

Treatment of neurologic disorders with inhibitors of 11beta-hsd1 Download PDF

Info

Publication number
WO2005060694A3
WO2005060694A3 PCT/US2004/042830 US2004042830W WO2005060694A3 WO 2005060694 A3 WO2005060694 A3 WO 2005060694A3 US 2004042830 W US2004042830 W US 2004042830W WO 2005060694 A3 WO2005060694 A3 WO 2005060694A3
Authority
WO
WIPO (PCT)
Prior art keywords
hsd1
treatment
inhibitors
neurologic disorders
11beta
Prior art date
Application number
PCT/US2004/042830
Other languages
French (fr)
Other versions
WO2005060694A2 (en
Inventor
Donna Oksenberg
Mehrdad Shamloo
Roman Urfer
Original Assignee
Agy Therapeutics Inc
Donna Oksenberg
Mehrdad Shamloo
Roman Urfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agy Therapeutics Inc, Donna Oksenberg, Mehrdad Shamloo, Roman Urfer filed Critical Agy Therapeutics Inc
Publication of WO2005060694A2 publication Critical patent/WO2005060694A2/en
Publication of WO2005060694A3 publication Critical patent/WO2005060694A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Methods and compositions for the treatment of neurologic disorders involving neuronal death, including but not limited to focal or global ischemia of the brain and central nervous system. In vivo inhibition of 11 beta hydroxysteroid dehydrogenase 1 (HSD1) is shown to be neuroprotective in these conditions. HSD1 inhibitors are administered alone or in combination with additional agents for prophylaxis or therapy.
PCT/US2004/042830 2003-12-18 2004-12-17 Treatment of neurologic disorders with inhibitors of 11beta-hsd1 WO2005060694A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53118203P 2003-12-18 2003-12-18
US60/531,182 2003-12-18
US57783504P 2004-06-07 2004-06-07
US60/577,835 2004-06-07

Publications (2)

Publication Number Publication Date
WO2005060694A2 WO2005060694A2 (en) 2005-07-07
WO2005060694A3 true WO2005060694A3 (en) 2007-10-04

Family

ID=34713784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/042830 WO2005060694A2 (en) 2003-12-18 2004-12-17 Treatment of neurologic disorders with inhibitors of 11beta-hsd1

Country Status (2)

Country Link
US (1) US20050137209A1 (en)
WO (1) WO2005060694A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0418877D0 (en) * 2004-08-24 2004-09-29 Univ Edinburgh Heart
US7622492B2 (en) * 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
US7645773B2 (en) * 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
US8475829B2 (en) 2006-04-06 2013-07-02 Nupathe Inc. Implants for the treatment of dopamine associated states
US20080124395A1 (en) * 2006-06-22 2008-05-29 Weiliam Chen Formulations and devices for treatment or prevention of neural ischemic damage
CA2819669A1 (en) * 2010-12-02 2012-06-07 Massachusetts Institute Of Technology Chemical and rnai suppressors of neurotoxicity in huntington's disease
EP3238724A3 (en) * 2012-06-01 2018-01-17 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
GB201303589D0 (en) 2013-02-27 2013-04-10 Univ Swansea Compound and method for the treatment of neurodegenerative conditions
CN111743898A (en) * 2020-06-11 2020-10-09 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Application of 11 beta-HSD 1inhibitor in protecting neural stem cells in stress environment
WO2024213728A1 (en) * 2023-04-12 2024-10-17 University Of Iceland Activators of the cold stress response and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
US7094792B2 (en) * 2001-11-22 2006-08-22 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100472694B1 (en) * 2000-12-30 2005-03-07 한국생명공학연구원 Flavanone derivatives and composition for preventing or treating blood lipid level-related diseases comprising same
AR040241A1 (en) * 2002-06-10 2005-03-23 Merck & Co Inc INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094792B2 (en) * 2001-11-22 2006-08-22 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme

Also Published As

Publication number Publication date
US20050137209A1 (en) 2005-06-23
WO2005060694A2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP3037421A3 (en) Mlk inhibitors and methods of use
WO2006099379A3 (en) Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
HK1149764A1 (en)
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
TW200509937A (en) Novel compounds and their use in therapy
WO2005089502A3 (en) Methods for the treatment of synucleinopathies
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
IL174734A0 (en) Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
WO2007030697A3 (en) Modulation of neurogenesis by hdac inhibition
WO2005060694A3 (en) Treatment of neurologic disorders with inhibitors of 11beta-hsd1
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2007075923A3 (en) Treatment of synucleinopathies
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2005065183A3 (en) Mitotic kinesin inhibitors
BRPI0411864A (en) combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
ATE439363T1 (en) IMIDAZO 2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
WO2004073607A3 (en) Use of steroids to treat ocular disorders
CA2534303A1 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
WO2004010924A3 (en) Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase